Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination. (27th June 2022)

• Record Type: Journal Article
• Authors: Amjadi, Maya F; Adyniec, Ryan R; Gupta, Srishti; Bashar, S Janna; Mergaert, Aisha M; Braun, Katarina M; Moreno, Gage K; O'Connor, David H; Friedrich, Thomas C; Safdar, Nasia; McCoy, Sara S; Shelef, Miriam A
• Is Part Of: Journal of infectious diseases. Volume 226:Number 11(2022)
• Page Start: 1897
• Page End: 1902
• Publication Date: 2022-06-27
• Subjects: antibody -- COVID-19 -- SARS-CoV-2; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac263
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Background: The consequences of past coronavirus disease 2019 (COVID-19) infection for personal and population health are emerging, but accurately identifying distant infection is a challenge. Anti-spike antibodies rise after both vaccination and infection and anti-nucleocapsid antibodies rapidly decline. Methods: We evaluated anti-membrane antibodies in COVID-19 naive, vaccinated, and convalescent subjects to determine if they persist and accurately detect distant infection. Results: We found that anti-membrane antibodies persist for at least 1 year and are a sensitive and specific marker of past COVID-19 infection. Conclusions: Thus, anti-membrane and anti-spike antibodies together can differentiate between COVID-19 convalescent, vaccinated, and naive states to advance public health and research. Abstract : Antimembrane antibodies persist for at least 1 year and are a sensitive and specific marker of past COVID-19 infection. Also, antimembrane and antispike antibodies together can differentiate between COVID-19 convalescent, vaccinated, and naive states.